๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Microwave processing of starch-based porous structures for tissue engineering scaffolds

โœ Scribed by Fernando G. Torres; Aldo R. Boccaccini; Omar P. Troncoso


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
705 KB
Volume
103
Category
Article
ISSN
0021-8995

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


In vivo response to starch-based scaffol
โœ A.J. Salgado; O.P. Coutinho; R.L. Reis; J.E. Davies ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 478 KB

## Abstract Our purpose was to evaluate the __in vivo__ endosseous response to three starchโ€based scaffolds implanted in rats (__n__ = 54). We implanted the three scaffold groups; a 50/50 (wt %) blend of corn starch and ethyleneโ€vinyl alcohol (SEVAโ€C), the same composition coated with a biomimetic

Polycaprolactone coated porous tricalciu
โœ Weichang Xue; Amit Bandyopadhyay; Susmita Bose ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 411 KB

## Abstract Polycaprolactone (PCL) was coated on porous tricalcium phosphate (TCP) scaffolds to achieve controlled protein delivery. Porous TCP scaffolds were fabricated using reticulated polyurethane foam as sacrificial scaffold with a porosity of 70โ€“90 vol %. PCL was coated on sintered porous TCP

Fabrication and in vitro degradation of
โœ Amit S. Mistry; Stacy H. Cheng; Tiffany Yeh; Elizabeth Christenson; John A. Jans ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 271 KB

## Abstract In this work, the fabrication and __in vitro__ degradation of porous fumarateโ€based/alumoxane nanocomposites were evaluated for their potential as bone tissue engineering scaffolds. The biodegradable polymer poly (propylene fumarate)/propylene fumarateโ€diacrylate (PPF/PFโ€DA), a macrocom

Three-dimensional porous scaffolds at th
โœ Daniel L. Coutu; Azizeh-Mitra Yousefi; Jacques Galipeau ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 356 KB

## Abstract In the last 20 years, more than 1,500 gene therapy clinical trials have been approved worldwide targeting a variety of indications, from inherited monogenic diseases to acquired conditions such as cancer, cardiovascular and infectious diseases. However, concerns about the safety and eff